



Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45–49 Year-Olds: A Cross-Sectional Study

Thomas F. Imperiale¹, John B. Kisiel², Steven H. Itzkowitz³, Bradley Scheu⁴, Emma Kate Duimstra⁵, Sandra Statz⁶, Barry M. Berger⁶, and Paul J. Limburg²

ABSTRACT

High-specificity colorectal cancer screening is desirable to triage patients <50 years for colonoscopy; however, most endorsed colorectal cancer screening tests have not been rigorously evaluated in younger populations. This prospective cross-sectional study determined the specificity of the multitarget stool DNA (mt-sDNA) test in an average-risk screening population of 45 to 49 year-olds. Specificity was the primary outcome and was measured in participants without colorectal cancer or advanced precancerous lesions [APL—advanced adenomas (AA), and sessile serrated lesions ≥ 10 mm], and in the subgroup of participants with negative colonoscopic findings. APL sensitivity was a secondary outcome. The evaluable cohort included those who completed the study without protocol deviations and had a usable mt-sDNA test. Of 983 enrolled participants, 816 formed the evaluable cohort, with a mean age of 47.8 (SD, 1.5) years; 47.7% were women. No participants had

colorectal cancer, 49 had APL, 253 had nonadvanced adenomas (NAA), and 514 had negative colonoscopic findings. mt-sDNA test specificity was 95.2% (95% CI, 93.4–96.6) in participants with NAA or negative findings [96.3% (confidence interval (CI), 94.3%–97.8%)] in those with negative findings, and did not differ by sex ($P = 0.75$) or race ($P = 0.36$) in participants with NAA or negative findings. Sensitivity for APL was 32.7% (CI, 19.9–47.5%), with most APL (83.7%) measuring 10–19 mm and none having high-grade dysplasia. The area under the ROC curve for discriminating between APL and lesser findings was 0.72 (CI, 0.64–0.81). mt-sDNA's high specificity would help minimize risk from unnecessary diagnostic procedures in this age group. This study shows that mt-sDNA has high specificity among average-risk 45 to 49-year olds, supporting its use as a noninvasive option for colorectal cancer screening.

Introduction

Colorectal cancer is the fourth most commonly diagnosed and second deadliest cancer in the United States in men and women combined (1). In 2018, over 140,000 diagnoses and 50,000 fatalities from colorectal cancer were estimated (2). While the incidence of colorectal cancer in individuals aged 55 years and older has been decreasing since the mid-1980s, it has been increasing in individuals 40 to 49 years old since the mid-1990s (3). Between 2005 and 2014, colorectal cancer

mortality increased in those 55 years old and younger (4), while colon cancer incidence rates increased 1.3% per year and rectal cancer rates increased 2.3% per year in adults ages 40 to 49 years between 2005 and 2013 (3). Consequently, the current American Cancer Society guidelines recommend average-risk colorectal cancer screening beginning at age 45 years (5), although other major guidelines recommend initiating average-risk colorectal cancer screening at 50 years in most demographic groups (6, 7).

While increasing, colorectal cancer in the 45 to 49 year-old age group remains very uncommon, with a population prevalence that is half of that in persons aged 50–54 years (33.1 cases per 100,000 vs. 59.5 cases per 100,000; ref. 8). The low population prevalence in this age group requires a screening test to have high specificity (along with good sensitivity) to minimize the number of false-positive tests, which would generate unnecessary and invasive diagnostic colonoscopy with its cost and risk that could outweigh the benefits. However, to date, most of the currently endorsed colorectal cancer screening tests have not been rigorously studied in younger age groups.

The multi-target stool DNA (mt-sDNA) test was approved by the FDA in 2014 for screening average-risk individuals ≥ 50 years old for colorectal cancer. A recent label expansion in 2019 approved the mt-sDNA test for average-risk individuals 45 to 49 years old. The mt-sDNA test is a noninvasive option

¹Indiana University School of Medicine, Indianapolis, Indiana. ²Mayo Clinic, Rochester, Minnesota. ³Icahn School of Medicine at Mount Sinai, New York, New York. ⁴Deaconess Clinic, Newburgh, Indiana. ⁵EmpiriQA LLC, Long Grove, Illinois. ⁶Exact Sciences Corporation, Madison, Wisconsin.

Note: Supplementary data for this article are available at Cancer Prevention Research Online (<http://cancerprevres.aacrjournals.org/>).

NIH Trial Registration: ClinicalTrials.gov, NCT03728348, <https://clinicaltrials.gov/ct2/show/NCT03728348?term=NCT03728348&rank=1>

Corresponding Author: Thomas F. Imperiale, Regenstrief Institute, Inc., 1101 West 10th Street, Indianapolis, IN 46202-2859. Phone: 317-274-9046; E-mail: timperiale@iu.edu

Cancer Prev Res 2021;XX:XX-XX

doi: 10.1158/1940-6207.CAPR-20-0294

©2021 American Association for Cancer Research.

recommended by the American Cancer Society, the United States Preventive Services Task Force (USPSTF), and other guideline organizations for average-risk colorectal cancer screening (5–7). The mt-sDNA test detects biomarkers associated with advanced colorectal neoplasia (colorectal cancer and advanced precancerous lesions). A positive test requires a colonoscopy. In a study of nearly 10,000 evaluable participants ages 50 and older at average risk of colorectal cancer, the mt-sDNA test was 92% sensitive for colorectal cancer and 87% specific among participants with nonadvanced adenomas (NAA) or negative findings on colonoscopy, while the sensitivity for advanced precancerous lesions (APL) was 42% (9).

In this study (NCT03728348), we evaluated the performance of the mt-sDNA test in average-risk participants ages 45 to 49 years. The primary aim was to quantify the specificity of the mt-sDNA test. A secondary aim was to determine the sensitivity of the mt-sDNA test for colorectal cancer and advanced precancerous lesions (APL).

Methods

We conducted a prospective, cross-sectional study of average-risk 45–49 year olds who were interested in having a screening colonoscopy. Potential study participants were identified through advertisement. The study sponsor, Exact Sciences, provided advertising materials for utilization by the sites. Each site was also allowed to develop its own materials for dissemination, which included flyers/posters, radio, and social media to recruit participants. In addition, Exact Sciences also conducted its own recruitment campaign through the clinical research organization (CRO) via online advertisement. Each mode of advertisement required approval by both the sponsor and the Institutional Review Board. Although the sponsor provided materials, sites were not required to advertise for the study.

Participants were enrolled at 31 sites in the United States from November 2018 through June 2019. Institutional Review Board (IRB) approval was obtained from Copernicus Group IRB, and all participants provided written informed consent prior to any study-related procedures. The study was conducted in accordance with legal and regulatory requirements, the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), the Declaration of Helsinki (World Medical Association), and applicable local regulatory requirements and laws.

Study population

Individuals aged 45 to 49 years who were average risk for colorectal cancer were eligible for enrollment. Other than age, inclusion and exclusion criteria were identical to those of the mt-sDNA pivotal study (DeeP-C; NCT01397747; ref. 9). To target average-risk persons, we excluded from consideration persons with overt rectal bleeding; a positive fecal occult blood

test (FOBT) or fecal immunochemical test (FIT) within the 6 months prior to enrollment, previous colonoscopy, or those who had undergone a double-contrast barium enema, CT colonography, or flexible sigmoidoscopy within 5 years of enrollment; prior colorectal resection for any reason other than sigmoid diverticular disease; a personal history of colorectal cancer or adenoma; a personal history of familial adenomatous polyposis (FAP), Lynch syndrome, or other hereditary cancer syndromes; a history of aerodigestive tract cancer; 2 or more first-degree relatives diagnosed with colorectal cancer; a first-degree relative diagnosed with colorectal cancer before age 60; a family history of FAP or Lynch syndrome; Cronkhite–Canada Syndrome; inflammatory bowel disease including chronic ulcerative colitis and Crohn’s disease; any condition that, in the opinion of the investigator, precluded participation in the study; or who were unwilling or unable to provide informed consent.

Procedures

Participants completed the mt-sDNA test, followed by a screening colonoscopy within approximately 60 days of enrollment. Stool was collected prior to bowel preparation procedures for colonoscopy. Stool samples were shipped to Exact Sciences Laboratories (Madison, WI) for processing. mt-sDNA test results were recorded as “positive,” “negative,” “sample could not be processed,” or “no result obtained.” For samples not collected according to the instructions for use or if there was no valid test result, a repeat sample was requested if collection could occur prior to the initiation of bowel preparation. A positive mt-sDNA test result was based on the FDA-approved logistic regression algorithm threshold score of ≥ 183 ; the algorithm is published as Supplementary Data (9). The algorithm and threshold score were prospectively determined and locked prior to analyzing pivotal trial data and, since the mt-sDNA test is qualitative, the component values of the mt-sDNA test are not reported separately (10). The test includes molecular assays for aberrantly-methylated *BMP3* and *NDRG4* promoter regions, mutant *KRAS*, and β -*actin* (a control gene for DNA quantity), and an immunochemical assay for human hemoglobin, none of which have individual thresholds or cutoffs.

Bowel preparation and colonoscopy were performed according to usual practice at each clinical site. All colonoscopies were performed blinded to mt-sDNA results. Source documentation included the quality of bowel preparation, cecal intubation, colonoscope withdrawal time (11), and colonoscopy findings including histopathology results for any excised or biopsied lesion. Lesion location (proximal, distal, or rectal) and size (mm) were recorded for all colorectal cancers and APLs. Participants were characterized on the basis of the histopathologic diagnosis of their most clinically significant lesion (the index lesion). The proximal colon was defined as the cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, right colon not otherwise specified, or an insertion depth >60 cm. The distal colon was defined as the descending colon, sigmoid colon, recto-sigmoid colon, left colon not

otherwise specified, or an insertion depth of 16 to 60 cm, inclusive. The rectum was defined as the rectum or an insertion depth of 0 to 15 cm, inclusive.

Histopathology was analyzed from biopsy and surgical specimens according to each site's local surgical pathologist. Index lesions were categorized as colorectal cancer (CRC), APL [high-grade dysplasia/carcinoma *in situ* of any size, villous growth pattern ($\geq 25\%$) of any size, adenomas ≥ 10 mm, and serrated lesion ≥ 10 mm], NAA, nonneoplastic findings (hyperplastic polyps, lymphoid aggregates, others), and negative (no colorectal neoplasia, no findings on colonoscopy, no biopsy taken). Diagnoses of advanced colorectal neoplasia (colorectal cancer or APL) required confirmation a central pathologist, with discrepant findings adjudicated through review and interpretation by a second central pathologist. All pathologists were blinded to mt-sDNA test results.

Outcomes and measures

The primary outcome was the specificity of the mt-sDNA test with colonoscopy as the reference standard. Specificity for advanced colorectal neoplasia was the primary endpoint. Specificity for any precancerous lesion, advanced or non-advanced, was also measured. We report APL sensitivity as a secondary outcome, despite the study's low prevalence for a precise estimate. We compared the area under the receiver operating characteristic (ROC) curve (AUC; ref. 12) and 95% CI for APL in 45 to 49 year-olds to the historical AUC and 95% CI for APL in ≥ 50 year-olds from the mt-sDNA pivotal study (9).

Statistical analysis

The primary analysis required a one-sided 97.5% lower bound for specificity of the mt-sDNA test to exceed 85.0%, which was the lower bound acceptability criteria for specificity from the mt-sDNA test pivotal study (9). The minimum number of nonadvanced neoplasia and negative subjects needed to rule out an 85.0% lower bound on the specificity with 90% power for a one-sided test with 2.5% type I error according to an exact binomial distribution was determined to be 225. A minimum sample size of 225 evaluable subjects (ages 45–49 inclusive) was required to adequately power the primary analysis. This minimum sample size requirement was adjusted to 731 nonadvanced neoplasia and negative subjects to more precisely estimate the specificity by narrowing the CI.

We included participants in the primary analysis if they completed the study without major protocol deviations, had a usable mt-sDNA test, and had a complete colonoscopy (the evaluable cohort). We also report analyses for participants who had a valid or usable mt-sDNA test and a reportable or complete colonoscopy (the intent-to-screen cohort). Participants with stool samples received outside of the 72-hour processing window for the mt-sDNA test and major protocol violations (did not meet inclusion/exclusion criteria) were excluded from the evaluable cohort but included in the intent-to-screen cohort.

mt-sDNA test specificity analysis confidence intervals were calculated using the exact binomial (Clopper–Pearson) method to compute the one-sided 97.5% confidence lower bound. Test performance by race, ethnicity, age, and gender subgroups were analyzed using χ^2 tests or Fisher exact test if the sample size for the categories being compared was < 5 . All CIs are reported as two-sided 95.0% CI. For the specificity primary endpoint, the lower bound of the two-sided 95.0% CI corresponds to a lower one-sided 97.5% CI.

Results

Study population

From 31 sites, 983 nonconsecutive participants were enrolled after providing informed consent; 876 participants underwent colonoscopy and submitted a stool sample, with 842 participants included in the intent-to-screen cohort and 816 participants included in the evaluable cohort (**Fig. 1**). Fifty-three participants submitted a stool sample but were excluded because they did not undergo colonoscopy, while 4 participants were excluded who underwent colonoscopy but did not submit a stool sample. The evaluable cohort had a mean age of 47.8 (SD, 1.5) years and was 47.7% female. All enrolled participants, the intent-to-screen cohort, and the evaluable cohort were similar in age, sex, and race/ethnicity (**Table 1**). Colonoscopy was completed in 89.6% of participants, with 742 (90.9%) having “good” or “excellent” quality bowel preparation. The mean time from the first mt-sDNA stool sample collection to first colonoscopy was 27 (SD, 19.4) days (Supplementary Table S1). Among 947 enrolled subjects who received a mt-sDNA test, 19 had an uninterpretable result, for a test failure rate of 2.0%.

Among all evaluable participants, 53 (6.5%) participants had a positive mt-sDNA test. No participants in the evaluable cohort had colorectal cancer, while 49 (6.0%) had APL, and 767 (94.0%) had either nonadvanced neoplasia ($n = 253$) or negative findings on colonoscopy ($n = 514$; **Fig. 1**). Of the APL, none had high-grade dysplasia/carcinoma *in situ*, 20.4% were adenomas characterized as villous or tubulovillous, 65.3% were adenomas ≥ 10 mm in size without other advanced features, and 14.3% were serrated lesions ≥ 10 mm in size. Index lesion distributions were similar in the intent-to-screen cohort and all enrolled participants (Supplementary Table S2). The majority (83.7%) of APL were 10–19 mm in size, with only 1 APL < 10 mm. APL were distributed among the proximal colon (40.8%), distal colon (42.9%), and rectum (16.3%) (Supplementary Table S3).

Multi-target stool DNA test performance

Among the 767 participants with either NAA or negative findings, mt-sDNA test specificity was 95.2% (CI, 93.4–96.6%) (**Table 2**). Specificity did not differ by sex (94.9% male vs. 95.4% female; $P = 0.75$) or race (94.5% white vs. 98.9% black or African American; $P = 0.36$ across all races). When considering only the 514 participants with negative findings, specificity was 96.3% (CI, 94.3–97.8%; **Table 2**). Because of the narrow age




Figure 1.
Flowchart for evaluable cohort.

range examined in this study, variations in specificity by age were not analyzed.

mt-sDNA test sensitivity for APL was 32.7% (95% CI, 19.9%–47.5%), detecting 16 of 49 APL (Table 2). The lack of colorectal cancer and low prevalence of APL did not permit further estimation of sensitivity by APL size or location. On the basis of APL test characteristics and 6.0% prevalence, other relevant study sample metrics include a positive predictive value of 30.2% (CI, 18.3%–44.3%), a negative predictive value of 95.7% (CI, 94.0%–97.0%), a positive likelihood ratio of 6.77 (CI, 4.06–11.28), and a negative likelihood ratio of 0.71 (CI, 0.58–0.86). The AUC was 0.72 (95% CI, 0.64–0.81) for discrimination between APL and lesser findings (NAA or negative findings) in participants 45–49 years (Fig. 2), nominally comparable to the historical AUC of 0.73 (95% CI, 0.69–0.74) for participants 50 years and older (9). The mt-sDNA collection kit incurred no adverse effects among the study participants.

Discussion

Performance characteristics of colorectal cancer screening tests in average-risk individuals ages 45–49 years are largely unknown. In this prospective, cross-sectional study of 983 participants, we examined the performance of the guideline-endorsed (5–7) mt-sDNA test in average risk participants aged 45–49 years with all participants undergoing colonoscopy as the reference standard. The mt-sDNA test demonstrated a high specificity (95.2%) in this age group, which is higher than in persons who are 50 years and older. The higher specificity in this younger age group is consistent with the expected lower prevalence of any colorectal neoplasia, lesions that cause bleeding, and lower background methylation in stool samples (13).

Test specificity, rather than sensitivity, was the primary outcome of this study for two reasons. First, the expected prevalence of colorectal cancer and APLs is lower in the 45

Table 1. Patient demographics for analysis cohorts.

Demographic features	All enrolled participants, N = 983	Intent-to-screen cohort ^a , N = 842	Evaluable cohort ^b , N = 816
Age (years)			
Mean (SD)	47.8 (1.5)	47.9 (1.5)	47.8 (1.5)
Sex, n (%)			
Male	518 (52.7%)	440 (52.3%)	427 (52.3%)
Female	465 (47.3%)	402 (47.7%)	389 (47.7%)
Race, n (%)			
White	803 (81.7%)	706 (83.8%)	685 (83.9%)
Black or African American	127 (12.9%)	95 (11.3%)	90 (11.0%)
Asian	41 (4.2%)	31 (3.7%)	31 (3.8%)
American Indian or Alaska Native	1 (0.1%)	1 (0.1%)	1 (0.1%)
Native Hawaiian or Other Pacific Islander	1 (0.1%)	1 (0.1%)	1 (0.1%)
Other	10 (1.0%)	8 (1.0%)	8 (1.0%)
Ethnicity, n (%)			
Hispanic or Latino	67 (6.8%)	48 (5.7%)	47 (5.8%)
Not Hispanic or Latino	916 (93.2%)	794 (4.3%)	769 (94.2%)

^aThe intent-to-screen cohort included participants with a valid or usable mt-sDNA and a reportable or complete colonoscopy.

^bThe evaluable cohort included only participants with a usable mt-sDNA and complete colonoscopy. Participants with stool samples received outside of the 72-hour mt-sDNA processing window, incomplete/not reportable colonoscopies, and other major protocol violations (inclusion/exclusion criteria not met) were excluded.

to 49-year-old age group. For a screening test to be viable in a low prevalence setting, it requires high specificity to minimize the costs and burdens resulting from false-positive test results. Our findings of no colorectal cancer in more than 800 evaluable participants, along with a low prevalence of APLs, supports this contention. Such low prevalence of advanced neoplasia precludes the feasibility of estimating mt-sDNA test sensitivity as the primary endpoint, because the required sample size needed to quantify sensitivity for colorectal cancer and APLs with reasonable precision would be nearly 20 times that of the current study. Second, there is no reason to expect a difference

in colorectal cancer sensitivity for persons aged 45–49 years from that in older persons, especially when the majority of early-onset colorectal cancer are located in the distal colon and rectum (14–15). Furthermore, in a recent study comparing tissue markers in colorectal cancer cases aged 40–44, 45–49, and 50–64 years, there were no statistically significant age-related differences in tissue distributions of *NDRG4*, *BMP3*, and *KRAS* (16). Finally, the 32.7% sensitivity for APLs is consistent with that of the pivotal study, although the relatively lower prevalence reduces the precision for this comparison.

Table 2. Test performance in the evaluable cohort.

Most advanced finding	Colonoscopy (N = 816) no.	mt-sDNA (N = 816)	
		Positive Results, no.	Specificity, % (95% CI)
All nonadvanced adenomas, non-neoplastic findings, and negative results on colonoscopy	767	37	95.2 (93.4–96.6)
Negative results on colonoscopy	514	19	96.3 (94.3–97.8)
		Prevalence, % (N = 816)	Sensitivity, % (95% CI)
Colorectal cancer	0	NA	NA
Advanced precancerous lesions ^a	49	6.0	32.7 (19.9–47.5)
High-grade dysplasia	0	<0.1	NA
Adenoma, villous growth pattern	10	1.2	60.0 (26.2–87.8)
Adenoma ≥10 mm	32	3.9	28.1 (13.7–46.7)
Serrated lesion ≥10 mm	7	0.9	14.3 (0.4–57.9)
Nonadvanced adenoma	253	31.0	7.1 (4.3–11.0)

Abbreviations: NA, not applicable; no., number.

^aOn the basis of most advanced lesion; therefore, prevalence estimates for less advanced lesions are biased downward.




Figure 2.

ROC curves for mt-sDNA test specificity. **A**, ROC for the evaluable cohort discriminating between advanced precancerous lesions and lesser findings (nonadvanced adenoma and negative colonoscopy). **B**, ROC for the evaluable cohort discriminating between advanced precancerous lesions and negative colonoscopy. AUC, area under the receiver operating characteristic; ROC, receiver operating characteristic.

With the ACS guidelines recommending initiation of average-risk colorectal cancer screening at age 45 (5), a noninvasive test with high specificity, such as the mt-sDNA test, is required to optimize resource utilization and to minimize the risk from more invasive procedures. Using noninvasive screening in this age group would identify individuals most likely to benefit from colonoscopy, thereby mitigating the impact of potential diversion of colonoscopy resources from higher risk patients to screening younger individuals with lower risks of colorectal cancer and APL (as evidenced by the current data showing no colorectal cancers and low prevalence of APL in this study population), as the latter are less likely to benefit from colonoscopy. Furthermore, patients under age 50 may be resistant to an invasive screening procedure but more amenable to a noninvasive test.

The mt-sDNA test, guaiac-based fecal occult blood test (gFOBT), and fecal immunochemical test (FIT) represent the noninvasive colorectal cancer screening options currently endorsed by major guidelines (5–7). In a large study comparing the mt-sDNA test to FIT in average risk individuals 50 years and older, the mt-sDNA test detected significantly more colorectal cancer and APL than FIT, while FIT had fewer false positive results (9). In the referenced study, however, mt-sDNA test specificity in 45 to 49 year-olds was 95.2%, which is similar to that of FIT in individuals ages 50 to 85 years (96.4%; ref. 9) and 40–49 years (97.4%; ref. 17). While colorectal cancer screening with the mt-sDNA test is recommended every 3 years, (5, 7, 18) gFOBT/FIT screening requires annual testing (5, 6). Increased test frequency may be burdensome to patients and negatively impact

longitudinal adherence. Over 3 to 5 years, adherence to annual gFOBT ranges between 14% and 48% (19–22). A high-performing, noninvasive test with a longer rescreening interval may be preferred for screening younger, average-risk individuals (23), as it balances the need to utilize colonoscopy resources efficiently with the potential for a higher degree of adherence with guideline recommendations.

We observed an APL prevalence of 6.0% in average-risk participants 45 to 49 years of age, which is consistent with a recent study that found an APL prevalence of 6.4% (24). Karsenti and colleagues found that APL prevalence in average-risk 45 to 49 year-olds was almost twice that in 40 to 44 year-olds.

On the basis of the test characteristics observed in this study population, we can speculate on how the mt-sDNA test would perform clinically in average-risk 45 to 49 year-olds. We observed a mt-sDNA test sensitivity of 32.7% for APL. As no participants with colorectal cancer were identified in the study, consistent with the low reported prevalence of colorectal cancer in this age group (25), the sensitivity of the mt-sDNA test for colorectal cancer could not be determined. Given a 6% prevalence of APL, a negative mt-sDNA test result reduces the risk of APL to 4.3% while a positive result increases APL risk 5-fold to 30.2%. If we assume a prevalence of colorectal cancer of 0.11% [prevalence = incidence \times duration; (31.4 cases/100,000 annually; ref. 5) \times (average 3–4 year duration; ref. 26) yields a prevalence between 0.09% and 0.13%, or an average of 0.11%]. in this age group and further assume colorectal cancer sensitivity of 92.3% based on performance in persons 50 to 85 years old (9), then a positive mt-sDNA test increases colorectal

cancer risk from 0.11% to 1.5% (a greater than 10-fold increase), while a negative result reduces colorectal cancer risk to 0.01% (a 10-fold reduction). While the assumption of colorectal cancer sensitivity requires validation, these calculations suggest that the mt-sDNA test potentially has a clinically important post-test effect on both colorectal cancer and APL risk when positive and on colorectal cancer risk when negative. Furthermore, as compared with screening this age group with colonoscopy, mt-sDNA would reduce this need by $(1 - 0.065 = 0.935) \times 93.5\%$, while potentially detecting nearly all CRC in a single application if colorectal cancer sensitivity of mt-sDNA is no different in 45 to 49 year-olds.

Limitations of this study warrant comment. One limitation is the low prevalence of advanced neoplasia (colorectal cancer and APL) observed in this age group, which precludes a precise estimate of mt-sDNA sensitivity. No study participants were found to have colorectal cancer or high-grade dysplasia. As adenomas with high-grade dysplasia are the category of APL most likely to develop into colorectal cancer, the lack of this finding limits the interpretation of the APL sensitivity reported here; no other mt-sDNA sensitivity data in 45 to 49 year-olds are reported. Nevertheless, the AUC for discrimination between APL and lesser findings is consistent with the AUC reported in participants 50 years and older (9), suggesting that mt-sDNA test performance is similar in 45 to 49 year-olds. A second potential study limitation is selection bias, as persons enrolled in this study self-selected to complete screening colonoscopy. We do not know how representative this population is and whether it represents the average-risk spectrum of adults 45 to 49 years old. Colorectal cancer screening guidelines have not previously included this age group; therefore, characteristics associated with colorectal cancer screening adherence in younger patients have not been well defined. While no data indicate that mt-sDNA test performance is affected by patient health, we cannot fully dismiss the possibility that the participants who agreed to enroll in this study may not represent the larger average-risk 45 to 49 year-old population.

Beyond study-specific limitations, those specific to the mt-sDNA test itself require consideration. Although cost has not been formally considered by the U.S. Preventive Services Task Force in its guideline recommendations, the cost difference between FIT (\$25–35) and mt-sDNA (\$595–\$695) is substantial. Compared with no screening, mt-sDNA is considered to be cost-effective (18, 27); however, when compared with any other screening test, incremental cost-effectiveness ratios exceed thresholds for cost-effectiveness under conditions of high screening adherence (28). A second concern of mt-sDNA use has been the scenario where colonoscopy is “negative” (i.e., no polyps), but the mt-sDNA test is positive. Such discordant findings raise the question of whether an evaluation for other aerodigestive cancers is required. Among 1,216 persons with a negative colonoscopy 205 (16.7%) of whom had discordant test results, there was no difference in the incidence of aerodigestive cancers between discordant and concordant groups with a 5.3–

5.4 year median follow-up, nor were the numbers of observed aerodigestive cancers different from the numbers expected based on SEER data (29). Finally, this study does not consider the important issues of patient preference, uptake, adherence, and cost, all of which are required to understand real-world performance of this (and any) screening test. Studies of mt-sDNA test uptake and its colorectal cancer sensitivity, in particular, are warranted in persons under 50 years to better characterize test performance in this age group.

Authors' Disclosures

T.F. Imperiale reports grants from Exact Sciences Corp during the conduct of the study. J.B. Kisiel reports grants and other from Exact Sciences during the conduct of the study; in addition, J.B. Kisiel has a patent for Detecting Colorectal Neoplasia 10370726 USA issued, licensed, and with royalties paid from Exact Sciences (and an inventor of intellectual property owned by J.B. Kisiel's employer, Mayo Clinic, which is licensed to Exact Sciences on which royalties may be earned, paid to the employer). S. Itzkowitz reports grants and personal fees from Exact Sciences Corporation during the conduct of the study. B. Scheu reports other from Exact Sciences during the conduct of the study. E.K. Duimstra reports personal fees from EmpiriQA, LLC during the conduct of the study. S.H. Statz is an employee and stock holder of Exact Sciences. B.M. Berger reports personal fees from Exact Sciences during the conduct of the study and personal fees from Exact Sciences outside the submitted work. P.J. Limburg serves as Chief Medical Officer for Screening at Exact Sciences through a contracted services agreement with Mayo Clinic. P.J. Limburg and Mayo Clinic have contractual rights to receive royalties through this agreement. No disclosures were reported by the other authors.

Authors' Contributions

T.F. Imperiale: Conceptualization, supervision, validation, methodology, writing-original draft, writing-review and editing. **J.B. Kisiel:** Writing-original draft, writing-review and editing. **S.H. Itzkowitz:** Writing-original draft, writing-review and editing. **B. Scheu:** Data curation, formal analysis, writing-original draft, writing-review and editing. **E.K. Duimstra:** Data curation, formal analysis, writing-original draft, writing-review and editing. **S. Statz:** Conceptualization, funding acquisition, writing-original draft, writing-review and editing. **B.M. Berger:** Conceptualization, funding acquisition, writing-original draft, writing-review and editing. **P.J. Limburg:** Conceptualization, funding acquisition, writing-original draft, writing-review and editing.

Acknowledgments

This study was funded by Exact Sciences. Exact Sciences was responsible for the design and conduct of the study. All authors were responsible for interpretation of the data and preparation and review of the manuscript. Medical writing and editorial support were provided by Rebecca K Swartz, PhD, a former employee of Exact Sciences (Madison WI), and William K. Johnson, a current employee of Exact Sciences (Madison, WI).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 8, 2020; revised October 1, 2020; accepted December 28, 2020; published first January 12, 2021.

References

- American Cancer Society. Cancer facts & figures 2019. Atlanta, GA: American Cancer Society; 2019.
- American Cancer Society. Cancer facts & figures 2018. Atlanta, GA: American Cancer Society; 2018.
- Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. *J Natl Cancer Inst* 2017;109:djw322.
- Siegel RL, Miller KD, Jemal A. Colorectal cancer mortality rates in adults aged 20 to 54 years in the United States, 1970–2014. *JAMA* 2017;318:572–4.
- Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin* 2018;68:250–81.
- US Preventive Services Task Force. Screening for colorectal cancer US preventive services task force recommendation statement. *JAMA* 2016;315:11.
- Rex DK, Boland RC, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. *Am J Gastroenterol* 2017;112:1016–30.
- Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin* 2020;70:145–64.
- Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med* 2014;370:1287–97.
- Exact Sciences Corporation Limited. Cologuard Physician Brochure. Available from: <https://www.cologuardtest.com/hs-fs/hub/377740/file-1412311339.pdf>.
- Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. *N Engl J Med* 2006;355:2533–41.
- CLSI. Assessment of the diagnostic accuracy of laboratory tests using receiver operating characteristic curves; Approved Guideline—Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. Available from: https://clsi.org/media/1425/ep24a2_sample.pdf.
- Ahlquist DA, Taylor WR, Yab TC, Devens ME, Mahoney DW, Boardman LA, et al. Aberrantly methylated gene marker levels in stool: effects of demographic, exposure, body mass, and other patient characteristics. *J Mol Biomark Diagn* 2012;3:100133.
- Wang Mo-J, Ping J, Li Y, Adell G, Arbmán G, Nodin B, et al. The prognostic factors and multiple biomarkers in young patients with colorectal cancer. *Sci Rep* 2015;5:10645.
- Kneuert PJ, Chang GJ, Hu C-Y, Rodriguez-Bigas MA, Eng C, Vilar E, et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. *JAMA Surg* 2015;150:402–9.
- Limburg PJ, Mahoney DW, Ahlquist DA, Allawi HT, Johnson SC, Kaiser M, et al. Comparison of tissue-based molecular markers in younger versus older patients with colorectal neoplasia. *Cancer Epidemiol Biomarkers Prev* 2020;29:1570–76.
- Kim NH, Park JH, Park DI, Sohn CI, Choi K, Jung YS. The fecal immunochemical test has high accuracy for detecting advanced colorectal neoplasia before age 50. *Dig Liver Dis* 2017;49:557–61.
- Berger BM, Schroy P III, Dinh TA. Screening for colorectal cancer using a multitarget stool DNA test: modeling the effect of the interval on clinical effectiveness. *Clin Colorectal Cancer* 2016;15:e65–74.
- Liang PS, Wheat CL, Abhat A, Brenner AT, Fagerlin A, Hayward RA, et al. Adherence to competing strategies for colorectal cancer screening over 3 years. *Am J Gastroenterol* 2016;111:105–14.
- Gellad ZF, Stechuchak KM, Fisher DA, Olsen MK, McDuffie JR, Østbye T, et al. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. *Am J Gastroenterol* 2011;106:1125–34.
- Cyhaniuk A, Coombes ME. Longitudinal adherence to colorectal cancer screening guidelines. *Am J Manag Care* 2016;22:105–11.
- van der Vlugt M, Grobbee EJ, Bossuyt PM, Bongers E, Spijker W, Kuipers EJ, et al. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. *Br J Cancer* 2017;116:44–9.
- Finney Rutten LJ, Jacobson RM, Wilson PM, Jacobson DJ, Fan C, Kisiel JB, et al. Early adoption of a multitarget stool DNA test for colorectal cancer screening. *Mayo Clin Proc* 2017;92:726–33.
- Karsenti D, Tharsis G, Burtin P, Venezia F, Tordjman G, Gillet A, et al. Adenoma and advanced neoplasia detection rates increase from 45 years of age. *World J Gastroenterol* 2019;25:447–56.
- Berg JW, Downing A, Lukes RJ. Prevalence of undiagnosed cancer of the large bowel found at autopsy in different races. *Cancer* 1970;25:1076–80.
- Zheng W, Rutter CM. Estimated mean sojourn time associated with hemoccult SENSE for detection of proximal and distal colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2012;21:1722–30.
- Naber SK, Knudsen AB, Zaubler AG, Rutter CM, Fischer SE, Pabiniak CJ, et al. Lansdorp-Vogelaar I. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. *PLoS One* 2019;14:e0220234.
- Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. *Gastroenterology* 2016;151:427–39.
- Berger BM, Kisiel JB, Imperiale TF, Geenen DJ, Heigh RI, Mahoney DW, et al. Low incidence of aerodigestive cancers in patients with negative results from colonoscopies, regardless of findings from multitarget stool DNA tests. *Clin Gastroenterol Hepatol* 2020;18:864–71.

Cancer Prevention Research

Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45–49 Year-Olds: A Cross-Sectional Study

Thomas F. Imperiale, John B. Kisiel, Steven H. Itzkowitz, et al.

Cancer Prev Res Published OnlineFirst January 12, 2021.

Updated version

Access the most recent version of this article at:
doi:[10.1158/1940-6207.CAPR-20-0294](https://doi.org/10.1158/1940-6207.CAPR-20-0294)

Supplementary Material

Access the most recent supplemental material at:
<http://cancerpreventionresearch.aacrjournals.org/content/suppl/2021/01/06/1940-6207.CAPR-20-0294.DC1>

E-mail alerts

[Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link
<http://cancerpreventionresearch.aacrjournals.org/content/early/2021/01/13/1940-6207.CAPR-20-0294>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.